phenobarbital has been researched along with Disease Exacerbation in 18 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy patients died (unrelated to seizures) and survival rates were equivalent in both groups (median survival = 6." | 2.71 | Prophylactic anticonvulsants in patients with brain tumour. ( Barnes, P; Brasher, PM; Cairncross, JG; DeAngelis, LM; Forsyth, PA; Fulton, D; Hagen, NA; Stewart, D; Sutherland, G; Weaver, S, 2003) |
| "Phenobarbital treated mice showed damped corticosterone levels and a less stable 24 hours activity rhythm as well as an increase in activity during the light phase, reminiscent of sleep disruption." | 1.62 | Relationship between locomotor activity rhythm and corticosterone levels during HCC development, progression, and treatment in a mouse model. ( Ali, AAH; Hassan, SA; Jänicke, RU; Korf, HW; Pfeffer, M; Sohn, D; von Gall, C; Yassine, M, 2021) |
| "Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease." | 1.51 | New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. ( Bosch, J; Boyer-Diaz, Z; Gracia-Sancho, J; Lozano, JJ; Maeso-Díaz, R; Ortega-Ribera, M; Peralta, C, 2019) |
| "Flupirtine is a KCNQ potassium channel opener." | 1.46 | Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy. ( Raol, YH; Sampath, D; Valdez, R; White, AM, 2017) |
| " Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population." | 1.31 | Influence of phenytoin on the disposition of irinotecan: a case report. ( Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002) |
| "Phenobarbital treatment increased the number of CYP2A5-positive centrilobular hepatocytes and the CYP2A5-positive areas were extended into the middle zone in all strains, but periportal hepatocytes remained negative." | 1.30 | Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions. ( Bursch, W; Camus-Randon, AM; Grasl-Kraupp, B; Lang, MA; Rossmanith, W; Schulte-Hermann, R; Wastl, UM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Maeso-Díaz, R | 1 |
| Boyer-Diaz, Z | 1 |
| Lozano, JJ | 1 |
| Ortega-Ribera, M | 1 |
| Peralta, C | 1 |
| Bosch, J | 1 |
| Gracia-Sancho, J | 1 |
| Zombori, L | 1 |
| Bacon, M | 1 |
| Wood, H | 1 |
| Chatterjee, F | 1 |
| Venkateswaran, R | 1 |
| Lampariello, S | 1 |
| Yoong, M | 1 |
| Hassan, SA | 1 |
| Ali, AAH | 1 |
| Yassine, M | 1 |
| Sohn, D | 1 |
| Pfeffer, M | 1 |
| Jänicke, RU | 1 |
| Korf, HW | 1 |
| von Gall, C | 1 |
| Sampath, D | 1 |
| Valdez, R | 1 |
| White, AM | 1 |
| Raol, YH | 1 |
| Kakehashi, A | 1 |
| Ishii, N | 1 |
| Okuno, T | 1 |
| Fujioka, M | 1 |
| Gi, M | 1 |
| Fukushima, S | 1 |
| Wanibuchi, H | 1 |
| Afzali, F | 1 |
| Salimi, M | 1 |
| Wang, NC | 1 |
| Good, LB | 1 |
| Marsh, ST | 1 |
| Treiman, DM | 1 |
| Uzüm, K | 1 |
| Caksen, H | 1 |
| Gündüz, Z | 1 |
| Ustünbaş, HB | 1 |
| Kandemir, O | 1 |
| Fujikawa, Y | 1 |
| Sugai, K | 1 |
| Hanaoka, S | 1 |
| Fukumizu, M | 1 |
| Sasaki, M | 1 |
| Kaga, M | 1 |
| Forsyth, PA | 1 |
| Weaver, S | 1 |
| Fulton, D | 1 |
| Brasher, PM | 1 |
| Sutherland, G | 1 |
| Stewart, D | 1 |
| Hagen, NA | 1 |
| Barnes, P | 1 |
| Cairncross, JG | 1 |
| DeAngelis, LM | 1 |
| Yang, X | 2 |
| Tang, J | 1 |
| Rogler, CE | 2 |
| Stanley, P | 3 |
| Eriksson, K | 1 |
| Metsäranta, P | 1 |
| Huhtala, H | 1 |
| Auvinen, A | 1 |
| Kuusela, AL | 1 |
| Koivikko, M | 1 |
| Bhaumik, M | 2 |
| Harris, T | 1 |
| Sundaram, S | 1 |
| Johnson, L | 1 |
| Guttenplan, J | 1 |
| Rogler, C | 1 |
| Wastl, UM | 1 |
| Rossmanith, W | 1 |
| Lang, MA | 1 |
| Camus-Randon, AM | 1 |
| Grasl-Kraupp, B | 1 |
| Bursch, W | 1 |
| Schulte-Hermann, R | 1 |
| Bhattacharyya, R | 1 |
| Gong, S | 1 |
| White, IN | 1 |
| Carthew, P | 1 |
| Davies, R | 1 |
| Styles, J | 1 |
| Brown, K | 1 |
| Brown, JE | 1 |
| Smith, LL | 1 |
| Martin, EA | 1 |
| Bauer, J | 1 |
| Burr, W | 1 |
| Murry, DJ | 1 |
| Cherrick, I | 1 |
| Salama, V | 1 |
| Berg, S | 1 |
| Bernstein, M | 1 |
| Kuttesch, N | 1 |
| Blaney, SM | 1 |
1 trial available for phenobarbital and Disease Exacerbation
| Article | Year |
|---|---|
Prophylactic anticonvulsants in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; | 2003 |
17 other studies available for phenobarbital and Disease Exacerbation
| Article | Year |
|---|---|
New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease.
Topics: Animals; Carbon Tetrachloride; Diet, High-Fat; Disease Models, Animal; Disease Progression; Fatty Li | 2019 |
Severe cortical damage associated with COVID-19 case report.
Topics: Acute Kidney Injury; Adolescent; Airway Extubation; Anticonvulsants; Blood Coagulation Disorders; Bo | 2021 |
Relationship between locomotor activity rhythm and corticosterone levels during HCC development, progression, and treatment in a mouse model.
Topics: Activity Cycles; Animals; Behavior, Animal; Biomarkers; Carcinoma, Hepatocellular; Chronotherapy; Ci | 2021 |
Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.
Topics: Aminopyridines; Animals; Animals, Newborn; Anticonvulsants; Brain; Disease Models, Animal; Disease P | 2017 |
Progression of Hepatic Adenoma to Carcinoma in
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenoma; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diseas | 2017 |
Unearthing Regulatory Axes of Breast Cancer circRNAs Networks to Find Novel Targets and Fathom Pivotal Mechanisms.
Topics: Breast Neoplasms; Computational Biology; Databases, Genetic; Disease Progression; Female; Gene Expre | 2019 |
EEG stages predict treatment response in experimental status epilepticus.
Topics: Analysis of Variance; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Disease Progressio | 2009 |
A fatal case of toxic epidermal necrolysis associated with liver cirrhosis.
Topics: Child; Disease Progression; Dose-Response Relationship, Drug; Emergency Service, Hospital; Fatal Out | 2003 |
[Three cases with severe motor and intellectual disabilities presenting the severest condition caused by prolonged non-convulsive status epilepticus].
Topics: Child, Preschool; Disabled Children; Disease Progression; Electroencephalography; Female; Humans; In | 2003 |
Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III.
Topics: Acetylglucosamine; Animals; Apoptosis; Carbohydrate Sequence; Carcinogens; Cell Division; Diethylnit | 2003 |
Treatment delay and the risk of prolonged status epilepticus.
Topics: Administration, Rectal; Anticonvulsants; Benzodiazepines; Child, Preschool; Clinical Protocols; Dise | 2005 |
Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression.
Topics: Acetylglucosamine; Animals; Carcinogens; Diethylnitrosamine; Disease Progression; Female; Genetic Ve | 1998 |
Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biomarkers, Tumor; Carcinogens; Cytochrome P-450 CYP2A6; Cyt | 1998 |
New evidence for an extra-hepatic role of N-acetylglucosaminyltransferase III in the progression of diethylnitrosamine-induced liver tumors in mice.
Topics: Alleles; Animals; Blotting, Northern; Blotting, Southern; Blotting, Western; Diethylnitrosamine; Dis | 2000 |
Short-term dosing of alpha-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats.
Topics: Animals; Animals, Genetically Modified; Carcinogens; Chromatography, High Pressure Liquid; Disease P | 2001 |
Course of chronic focal epilepsy resistant to anticonvulsant treatment.
Topics: Adult; Anticonvulsants; Carbamazepine; Cluster Analysis; Disease Progression; Documentation; Drug Ad | 2001 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2002 |